Videos

“I think as urologists, we need to become more comfortable with the female pelvic floor,” says Ava Saidian, MD.

"There's something coming out of Canada. It's a kiwi extract, which is a natural collagenase that comes from kiwi," says Landon Trost, MD.

“Before long, what we do, how we do it, and when we do it might solely be based off of those genetic testing results,” says Tim Richardson, MD.

“Time will tell as we move forward, but it has allowed us to use MDT, with or without ADT and ARPIs, to potentially look at hormone-free treatments,” says Jason M. Hafron, MD, CMO.

"I think that now we have good data that patient-reported outcomes have to be considered in these patient populations," says Andrew C. Peterson, MD, MPH.

"This year, we are starting an international rotation with a focus on global health and humanitarian work," says Akanksha Mehta, MD, MS.

"Every practice is going to be a little bit different on how they would like to approach this," says Michael Jenson, PA-C.

Panelists discuss how recent data from the EMBARK study indicates that in patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) at high risk for biochemical recurrence (BCR), enzalutamide combined with gonadotropin-releasing hormone (GnRH) significantly improves metastasis-free survival compared with monotherapy options, with no new safety signals reported.

"I joke that on face value, the APPs work for me, but I feel like I'm really working for them, because they basically do everything except for the surgery," says Andrew Y. Sun, MD.

"This has been exciting from a physician-surgeon standpoint," says Helen L. Bernie, DO, MPH.

Specifically, Jayram highlights pembrolizumab, nadofaragene firadenovec-vncg, and N-803 (Anktiva).

"Whenever they discuss germline testing, an important part of that is this pretest counseling process where you talk about the pros and the cons," says Daniel Kwon, MD.

APPs can help in introducing genetic testing and in the interpretation of results, according to Kara Cossis, PA-C, MPH.

“And you look at most of the trials that were done in this space, about 2/3 of time, over 60% of time, management was changed based on a PET scan,” says Jason Hafron, MD.

"What we found is that it's very difficult to raise your review on these websites, but fairly easy to drop your review," says Jake Miller, MD.

Katie S. Murray, DO, provides an overview of BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), defining it as a form of bladder cancer that does not respond to BCG therapy and explaining how it differs from BCG-responsive NMIBC in terms of treatment outcomes and disease progression.

“Put another way, with Apple Vision Pro, what we're hoping to do is have our residents be able to put on a headset and walk through a case before they actually walk into an operating room,” says Vikram M. Narayan, MD.

"I think what we definitively have is a device that's been around for over 50 years now that now we know significantly improves quality of life," says Andrew C. Peterson, MD, MPH.

Tim A. Richardson, MD, outlines the 2 key scenarios for utilizing genetic testing in clinical practice.

"It's often a balancing act of truly kind of pinning down people on what exactly they want to treat," says Landon Trost, MD.

“The 1 main assumption that we've been very wrong on although we've had the data for a long period of time, [is that] although we assume that the stone fragments are small enough to pass, oftentimes they don't,” says Thomas Mueller, MD.

"[Veterans] may be missing out on potentially life-saving treatments, and their family might also be missing out on some benefits as well," says Daniel Kwon, MD.

“It's really a reapplication of the existing technology for BPH that is familiar to many of us already and we use in our clinical practices,” says Arvin K. George, MD.

“Opportunity wise, I always say that if you don't perform the test, then you're limiting treatment options for your patients,” says Kara Cossis, PA-C, MPH.

“When a patient knows that there are so many tools that are there for people, it gives them hope. It gives their caregivers hope,” says Joy Maulik, CRNP.

"It's a little tedious to find these patients, but it's really critical. Otherwise, you're not going to get reimbursed for these therapies," says Jason Hafron, MD.

“We then talked a little bit about BCG unresponsive disease, which is a really hot topic,” says Gautam Jayram, MD.

“We're really excited as robotic surgeons, because this will be the first time in a couple decades that there'll be competition for robots, and that's only going to make things better,” says Ronney Abaza, MD, FACS.

“The guidelines have changed. They used to be called third-line therapies, and they're no longer quote "third-line" anymore, based on the new guidelines that have come out,” says Kari Bailey, MD.

Panelists discuss how management options for nonmetastatic castration-sensitive prostate cancer (nmCSPC) include active surveillance, radiotherapy, and systemic therapy, with recommendations influenced by factors such as tumor volume, prostate-specific antigen (PSA) doubling time, and patient life expectancy, particularly for those with high-volume symptomatic disease.